21-Gene recurrence scores
21-Gene recurrence scores
复制标题
DOI：
10.1002/cncr.26180
复制
发表时间：
2012-02-01
期刊：
影响因子：
6.2
通讯作者：
O'Regan, Ruth M.
中科院分区：
文献类型：
--
作者：
Lund, Mary Jo;Mosunjac, Marina;O'Regan, Ruth M.
背景：非裔美国人（AA）女性的乳腺癌死亡率高于白色（W）女性。这些差异甚至在雌激素受体（ER）阳性乳腺癌中也存在。21基因复发评分（RS）根据RS评分低风险（RS，0-18）、中等风险（RS，19-31）和高风险（RS，>31）预测ER阳性/淋巴结阴性乳腺癌患者的复发。高风险组最有可能从化疗中获益，从激素治疗中获益最小，并表现出较低的ER水平（固有管腔B癌）。在目前的研究中，作者调查了RS测试，评分，治疗和结局的种族差异。方法：来自亚特兰大3家医院的肿瘤登记数据确定了2005年至2009年期间诊断为乳腺癌的女性。病历摘要提供了RS和其他肿瘤/治疗因素的信息。统计分析采用卡方/精确检验和logistic回归。研究结果：在2186名患者中，包括1192名AA妇女和992名W妇女，853名妇女患有I期或II期ER阳性/淋巴结阴性疾病，因此符合RS检测的条件（AA 372 [31.2%]; W 481 [48.5%]; P
BACKGROUND: African American (AA) women experience higher breast cancer mortality than white (W) women. These differences persist even among estrogen receptor (ER)-positive breast cancers. The 21-gene recurrence score (RS) predicts recurrence in patients with ER-positive/lymph node-negative breast cancer according to RS scorelow risk (RS, 0-18), intermediate risk (RS, 19-31), and high risk (RS, >31). The high-risk group is most likely to benefit from chemotherapy, to achieve minimal benefit from hormonal therapy, and to exhibit lower ER levels (intrinsically luminal B cancers). In the current study, the authors investigated racial differences in RS testing, scores, treatment, and outcome. METHODS: Tumor registry data from 3 Atlanta hospitals identified women who were diagnosed with breast cancers during 2005 through 2009. Medical record abstraction provided information on RS and other tumor/ treatment factors. Statistical analyses used chi-square/ exact tests and logistic regression. RESULTS: Of 2186 patients, including 1192 AA women and 992 W women, 853 women had stage I or II, ER-positive/ lymph node-negative disease and, thus, were eligible for RS testing (AA 372 [31.2%]; W 481 [48.5%]; P